Leukemia Therapeutics Market- By Treatment Type, By Type of Leukemia, By Molecule Type - Regional Outlook, Competitive Strategies, and Segment Forecasts to 2030

Description

According to SPER Market Research, the Global Leukemia Therapeutics Market is estimated to reach USD 35.96 billion by 2030 with a CAGR of 11.3%.

Leukemia is a type of blood cancer that affects the bone marrow and lymphatic system. It affects leucocytes, or white blood cells, as the name implies. The DNA of leucocytes is broken in this type of cancer, causing them to proliferate and divide uncontrollably. These cells continue to develop and accumulate, preventing healthy white blood cells from forming and functioning.

Leukemia can be acute or chronic, affecting both red blood cells and platelets. Fever, night sweats, weight loss, an enlarged liver, frequent infections, and swollen lymph nodes are all common symptoms of leukemia. Some of the numerous kinds of leukemia are acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, and chronic lymphocytic leukemia. Acute myeloid leukemia, also known as acute myelogenous leukemia, is most common in adults.

Because of the increased number of people suffering from leukemia, technical improvements and breakthroughs in the field of blood cancer testing are driving the Global Leukemia Therapeutics Market. Furthermore, rising public awareness about the importance of preventive healthcare is likely to drive the market throughout the forecast period. Government initiatives and policies encouraging cancer awareness are expected to drive market expansion until 2026.

Impact of COVID-19 on the Global Leukemia Therapeutics Market

The risk of infection is low in treating Leukemia during COVID-19 times. Although the mortality rate maybe be higher in patients with leukemia and COVID-19. Furthermore, according to the study "Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicentre Study During the COVID-19 Outbreak," published in Cancer Discovery in June 2021, the risk of severe COVID-19 infection was found to be higher, at around 57 percent, among patients with blood cancers.

Scope of the Report:

Report Metric Details

Market size available for years 2019-2030

Base year considered 2021

Forecast period 2022-2030

Segments covered By Treatment Type, By Type of Leukemia, By Molecule Type

Geographies covered North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Companies Covered AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company Ltd., Gilead Sciences Inc. ICell Gene therapeutics, Merck & Company Inc., Novartis AG, Otsuka Holdings Company Ltd., Pfizer Inc., Roche HoldingAG, Stemline Therapeutics Inc., Takeda Pharmaceutical Company Ltd.

Global Leukemia Therapeutics Market, By Treatment Type:

Based on the Treatment Type, Global Leukemia Therapeutics Market is segmented as; Chemotherapy, Immunotherapy, Targeted Therapy, and Other Treatments

Global Leukemia Therapeutics Market, By Type of Leukemia:

Based on the Type of Leukemia, Global Leukemia Therapeutics Market is segmented as; Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, and Other Type of Leukemias.

Global Leukemia Therapeutics Market, By Molecule Type:

Based on the Molecule Type, Global Leukemia Therapeutics Market is segmented as; Small Molecules and Biologics.

Global Leukemia Therapeutics Market, By Region:

The Asia Pacific emerged as the leading region in the Global Leukemia Therapeutics Market with the maximum market share in 2021.

Product Code: HLCA2210

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1 Research data source
- 2.1.1 Secondary data
- 2.1.2 Primary data
- 2.1.3 SPER's internal database
- 2.1.4 Premium insight from KOL's
2.2 Market size estimation
- 2.2.1 Top-down and Bottom-up approach
2.3 Data Triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity, and Challenges Analysis
- 4.1.1 Drivers
- 4.1.2 Restraints
- 4.1.3 Opportunities
- 4.1.4 Challenges
4.2. COVID-19 Impacts on the Global Leukemia Therapeutics Market

5. Market variables and outlook

5.1. SWOT analysis
- 5.1.1 Strengths
- 5.1.2 Weaknesses
- 5.1.3 Opportunities
- 5.1.4 Threats
5.2. PESTEL analysis
- 5.2.1 Political landscape
- 5.2.2 Economic landscape
- 5.2.3 Social landscape
- 5.2.4 Technological landscape
- 5.2.5 Environmental landscape
- 5.2.6 Legal landscape
5.3. PORTER'S five forces analysis
- 5.3.1 Bargaining power of suppliers
- 5.3.2 Bargaining power of Buyers
- 5.3.3 Threat of Substitute
- 5.3.4 Threat of new entrant
- 5.3.5 Competitive rivalry
5.4. Heat map analysis

6. Global Leukemia Therapeutics Market, By Treatment Type, 2019-2030 (USD Million)

6.1. Chemotherapy
6.2. Immunotherapy
6.3. Targeted Therapy
6.4. Other Treatments

7. Global Leukemia Therapeutics Market, By Type of Leukemia, 2019-2030(USD Million)

7.1. Acute Lymphocytic Leukemia
7.2. Acute Myeloid Leukemia
7.3. Chronic Lymphocytic Leukemia
7.4. Chronic Myeloid Leukemia
7.5. Other Type of Leukemias

8. Global Leukemia Therapeutics Market, By Molecule Type, 2019-2030 (USD Million)

8.1. Small Molecules
8.2. Biologics

9. Global Leukemia Therapeutics Market, By Region, 2019-2030 (USD Million)

9.1. North America
- 9.1.1. United States
- 9.1.2. Canada
- 9.1.3. Mexico
9.2. Europe
- 9.2.1. Germany
- 9.2.2. United Kingdom
- 9.2.3. France
- 9.2.4. Italy
- 9.2.5. Spain
- 9.2.6. Rest of Europe
9.3. Asia-Pacific
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. India
- 9.3.4. Australia
- 9.3.5. South Korea
- 9.3.6. Rest of Asia-Pacific
9.4. South America
- 9.4.1. Brazil
- 9.4.2. Argentina
- 9.4.3. Rest of South America
9.5. Middle East & Africa
- 9.5.1. Kingdom of Saudi Arabia
- 9.5.2. United Arab Emirates
- 9.5.3. Rest of Middle East & Africa

10. Company Profiles

10.1 AbbVie Inc.
- 10.1.1. Company details
- 10.1.2. Financial outlook
- 10.1.3. Product summary
- 10.1.4. Recent developments
10.2 Amgen Inc.
- 10.2.1. Company details
- 10.2.2. Financial outlook
- 10.2.3. Product summary
- 10.2.4. Recent developments
10.3 Astellas Pharma Inc.
- 10.3.1. Company details
- 10.3.2. Financial outlook
- 10.3.3. Product summary
- 10.3.4. Recent developments
10.4 AstraZeneca PLC
- 10.4.1. Company details
- 10.4.2. Financial outlook
- 10.4.3. Product summary
- 10.4.4. Recent developments
10.5 Bristol-Myers Squibb Company
- 10.5.1. Company details
- 10.5.2. Financial outlook
- 10.5.3. Product summary
- 10.5.4. Recent developments
10.6 Eli Lilly and Company Ltd.
- 10.6.1. Company details
- 10.6.2. Financial outlook
- 10.6.3. Product summary
- 10.6.4. Recent developments
10.7 Gilead Sciences Inc.
- 10.7.1. Company details
- 10.7.2. Financial outlook
- 10.7.3. Product summary
- 10.7.4. Recent developments
10.8 iCell Gene therapeutics
- 10.8.1. Company details
- 10.8.2. Financial outlook
- 10.8.3. Product summary
- 10.8.4. Recent developments
10.9 Merck & Company Inc.
- 10.9.1. Company details
- 10.9.2. Financial outlook
- 10.9.3. Product summary
- 10.9.4. Recent developments
10.10 Novartis AG
- 10.10.1. Company details
- 10.10.2. Financial outlook
- 10.10.3. Product summary
- 10.10.4. Recent developments
10.11 Otsuka Holdings Company Ltd.
- 10.11.1. Company details
- 10.11.2. Financial outlook
- 10.11.3. Product summary
- 10.11.4. Recent developments
10.12 Pfizer Inc.
- 10.12.1. Company details
- 10.12.2. Financial outlook
- 10.12.3. Product summary
- 10.12.4. Recent developments
10.13 Roche Holding AG
- 10.13.1. Company details
- 10.13.2. Financial outlook
- 10.13.3. Product summary
- 10.13.4. Recent developments
10.14 Sanofi
- 10.14.1. Company details
- 10.14.2. Financial outlook
- 10.14.3. Product summary
- 10.14.4. Recent developments
10.15 Stemline Therapeutics Inc.
- 10.15.1. Company details
- 10.15.2. Financial outlook
- 10.15.3. Product summary
- 10.15.4. Recent developments
10.16 Takeda Pharmaceutical Company Ltd.
- 10.16.1. Company details
- 10.16.2. Financial outlook
- 10.16.3. Product summary
- 10.16.4. Recent developments